Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh

KKRX:950210
3,750.00
KRW
+5.00
(+0.13%)
-2,030.29EPS
388.22BMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
2.7
11.49
237.85
433.83
431.22
Basic EPS, GAAP
-351.6
-143.2
-3,519.2
293.6
-549
370.2
-1,522.54
-1,513.15
Free Cash Flow per Basic Share
-730.41
-650.19
-1,897.65
-2,103.76
-1,267.7
-1,642.12
-1,120.1
-1,120.34
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
11,464.91
9,567.35
7,154.13
7,496.5
7,306.41
6,839.2
7,188.96
7,188.96
Tangible Book Value per Share
3,560.03
7,753.2
6,067.34
5,517.81
5,080.73
3,619.89
3,864.16
3,864.16
Basic Weighted Avg Shares
43
52
60
60
60
60
60
60
Sales/Revenue/Turnover
- -
- -
- -
162
689
14,326
26,072
25,909
Operating Margin (%)
- -
- -
- -
659.44
-9,106.36
-470.14
-359.06
-357.34
Depreciation Expense
1,185
1,667
3,867
11,650
16,267
21,801
32,757
- -
Net Income, GAAP
-14,997
-7,391
-211,450
17,569
-32,921
22,297
-91,499
-90,915
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
10,855.89
-4,777.6
155.64
-350.95
-350.9
Working Capital
41,335
445,890
269,771
176,588
104,494
44,682
-36,192
-36,192
LT Debt
2,435
3,571
2,656
51,516
40,871
33,139
24,557
24,557
Total Equity
137,799
574,961
429,936
546,235
515,502
508,311
504,396
504,396
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-2.07
-42.08
3.99
-7.4
5.25
-21.71
-21.57

Capital Structure

KRW

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
57,279
61,097
81,018
LT Borrowings
27,136
24,462
21,777
LT Finance Leases
497
384
2,781
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
772,236
588,341
388,221

Working Capital

KRW

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
120,897
106,460
108,462
Cash, Cash Equivalents & STI
84,964
65,894
65,954
Accounts Receivable, Net
2,465
495
3,819
Inventories
30,429
35,543
32,757
Total Current Liabilities
117,729
125,133
144,654
Payables & Accruals
- -
- -
- -
ST Debt
57,279
61,097
81,018
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1.19%
-0.77%
Free Cash Flow
- -
41.75%
-31.94%
Net Income, GAAP
- -
337.43%
-510.36%
Sales/Revenue/Turnover
- -
- -
81.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
67
119
639
-137
689
2025
2,222
3,115
3,340
5,526
14,326
2026
2,308
7,704
509
15,388
26,072

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-152
-215.8
-23.8
-154.51
-549
2025
-95.2
-220.4
838.4
-146.03
370.2
2026
-205
-252.2
-340.8
-714.76
-1,522.54

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
So-Yeon Park
Full Time Employees
64
Sector
Health technology
Industry
Biotechnology
Address
#04-24 Nucleos South Building Singapore CE Singapore 138567
IPO Date
Feb 5, 2021
Business
Prestige BioPharma Limited (950210.KS) develops biosimilars, first-in-class antibody drugs and vaccines for infectious diseases. The Singapore-headquartered biopharmaceutical company, founded in 2015, operates R&D campuses in Singapore and Korea, including the Innovation Discovery Center in Busan and a CDMO facility through Prestige Biologics in Osong, Korea; it targets oncology, autoimmune disorders and unmet needs such as pancreatic cancer across global markets. Core products and pipeline include biosimilars Tuznue (HD201, trastuzumab biosimilar for HER2-positive breast and gastric cancers, Phase III complete), HD204 (bevacizumab biosimilar for solid tumors, Phase III), PBP1502 (adalimumab biosimilar for arthritis, Phase I) and over 12 additional candidates; first-in-class antibodies such as ulenistamab (PBP1510, PAUF-targeted for pancreatic cancer with FDA/EMA Orphan Drug and Fast Track designations, Phase 1/2a ongoing globally); next-generation vaccines including COVID-19 candidates; and diagnostics like the PAUF Pancreatic Cancer Detection Kit. Recent developments encompass European Commission marketing authorization for Tuznue in September 2024, marking the first biosimilar approval for a Singaporean firm in the EU following positive CHMP opinion in July 2024; licensing and supply agreements with Teva for European commercialization in October 2025, Dr. Reddy’s, Tabuk, Cipla and Pharmapark for global markets generating milestone payments, and Biosidus for Latin America in November 2025; opening of the Innovation Drug Center as an R&D hub; and participation in BIO USA 2025 to expand CDMO partnerships.